Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

BACKGROUNDS: In advanced pancreatic ductal adenocarcinoma (PDAC), immune therapy, including immune checkpoint inhibitors, has limited efficacy, encouraging the study of combination therapy. METHODS: Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry, immunofluorescence, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaozhen, Lao, Mengyi, Xu, Jian, Duan, Yi, Yang, Hanshen, Li, Muchun, Ying, Honggang, He, Lihong, Sun, Kang, Guo, Chengxiang, Chen, Wen, Jiang, Haitao, Zhang, Xiaoyu, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906048/
https://www.ncbi.nlm.nih.gov/pubmed/35260434
http://dx.doi.org/10.1136/jitc-2021-003982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906048/
https://www.ncbi.nlm.nih.gov/pubmed/35260434
http://dx.doi.org/10.1136/jitc-2021-003982

Ejemplares similares